![]() |
|
|
Vol. 302, Issue 2, 651-658, August 2002
Institute of Veterinary Pharmacology (R.W., M.M., D.S.H., G.S.),
Department of Urology (B.W., U.E.S., H.D.), University of Bern, Bern,
Switzerland; and Environmental Toxicology Program, National Institute
of Environmental Health Sciences (C.J.P.), Research Triangle Park,
North Carolina
The relaxing property of the K+ channel opener and nitric
oxide donor nicorandil and the new K+ channel opener PKF
217-744b was investigated on isolated human ureteral tissue in vitro
and in intact ureters of anesthetized pigs in vivo. In addition,
nicorandil and its antagonists, glibenclamide and methylene blue, were
tested on isolated pig ureter tissue in vitro. Nicorandil decreased the
frequency of spontaneous contractions in isolated pig ureter rings.
This effect was antagonized by glibenclamide and methylene blue
suggesting that the nicorandil induced relaxation of the ureter is
mediated by activation of ATP-sensitive K+ channels and
involvement of soluble guanylate cyclase. Moreover, nicorandil and PKF
217-744b reduced the amplitude of electrically induced contractions in
isolated human ureter rings. Calculations of EC50 values
showed that PKF 217-744b [EC50 = 4.83 × 10
8 M] was more potent than nicorandil
[EC50 = 4.38 × 10
5 M]. Both
drugs reduced the contraction frequency of the pig ureter after
intravenous and topical administration in vivo. Intravenous, but not
topical, administration of nicorandil and PKF 217-744b significantly
decreased arterial blood pressure but did not affect the heart rate.
The in vitro findings suggest that K+ channel opening and
nitric oxide release mediate the effect of nicorandil. Our in vivo
results indicate that PKF 217-744b and nicorandil are promising drugs
for clinical application in patients with acute stone colic to relieve
obstruction and facilitate stone passage or to relax the ureter before ureteroscopy.